News | Mammography | August 18, 2022

The new deal will secure expanded access to essential solutions that will help ensure radiologists, technologists and other healthcare professionals can drive greater productivity and meet higher oncology screening demand, while improving patient care 

The new deal will secure expanded access to essential solutions that will help ensure radiologists, technologists and other healthcare professionals can drive greater productivity and meet higher oncology screening demand, while improving patient care

August 18, 2022 —  Intelerad Medical Systems, a leading global provider of enterprise medical imaging solutions, today announced its acquisition of PenRad Technologies, Inc. (PenRad), a software provider for enhancing productivity for breast imaging and lung screening. The acquisition will expand Intelerad’s product offerings for mammography and lung analytics, optimizing workflows for radiologists and boosting health outcomes for patients. 

Founded in 1995, PenRad’s three core product offerings – PenRad for breast imaging, PenLung for lung screening, and PenTrac for patient tracking and reporting – have a proven track record of eliminating overhead costs, decreasing liability exposure and increasing patient satisfaction for innovative enterprise systems and diagnostic imaging centers and facilities. With the company’s next-generation technology and dedicated client support, PenRad is leading the way in automated diagnostic radiology. 

“Cancer affects all of us, whether you’ve personally been diagnosed or have witnessed a family member, friend or loved one suffer from the disease. PenRad was founded to help drive actionable change for not only my own family's breast cancer, but for millions of other individuals,” said Greg Gustafson, Founder and President of PenRad. “As our company heads into this next chapter, I’m excited to partner with Intelerad to further grow, scale, and impact patient lives and the healthcare industry at large.” 

Notably, the mammography market is expected to increase by more than 20% in the next several years, while the lung cancer diagnostics market is expected to reach $3.4 billion by 2026. PenRad is at the front lines of care as demand surges. 

Cancer screenings, and most notably, mammograms, drastically decreased during the COVID-19 pandemic as many healthcare facilities were temporarily closed and others faced severe staffing shortages. As the demand for scans continues to rise to pre-pandemic levels, innovative tools and technologies are critical to ensuring providers can meet the influx of patients, and that such screenings and scans are readily available to further improve overall health outcomes. 

“The acquisition of PenRad is an exciting milestone for Intelerad. Our global team of dreamers and doers are committed to improving healthcare through innovative technology, which means delivering the best-in-class systems our industry needs to improve the overall health of all populations,” said Mike Lipps, CEO, Intelerad. “Lung and breast cancer impact millions of individuals, and screenings play a major role in saving lives. By integrating PenRad’s core solutions into our company, we can ensure all patients have access to the scans they need to decrease health risks, while at the same time offering healthcare systems greater productivity.” 

This acquisition follows Intelerad’s recent investment by TA Associates. As global demand for scalable imaging and workflow solutions continues to increase, Intelerad will continue to fulfill its mission of providing clients with one of the most scalable imaging platforms in the world, enabling them to drive clinical efficiency and focus on providing enhanced patient care. 

For more information: www.intelerad.com 


Related Content

Feature | Radiology Imaging

View the September/October digital edition of Imaging Technology News (ITN), including links to videos, comparison ...

Time September 29, 2022
arrow
News | Radiation Oncology

September 28, 2022 — Populations in U.S. counties defined as more vulnerable based on social factors including ...

Time September 28, 2022
arrow
News | Breast Imaging

September 26, 2022 — The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to ...

Time September 26, 2022
arrow
News | Breast Density

September 22, 2022 — DenseBreast-info.org (DB-i) announced that it will host the inaugural #WorldDenseBreastDay on ...

Time September 22, 2022
arrow
News | Ultrasound Women's Health

September 21, 2022 — Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through the power ...

Time September 21, 2022
arrow
Feature | Breast Imaging | By Christine Book

Findings from a clinical trial that used artificial intelligence (AI) in an effort to reduce false positives on breast ...

Time September 21, 2022
arrow
News | MRI Breast

September 16, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), the contrast-enhanced in-phase Dixon ...

Time September 16, 2022
arrow
News | Breast Imaging

September 14, 2022 — When double reading screening mammograms, radiographers (technologists) trained for the task ...

Time September 14, 2022
arrow
News | Ultrasound Imaging

September 9, 2022 — Boston Imaging, the United States headquarters of Samsung digital radiography and ultrasound ...

Time September 09, 2022
arrow
News | Ultrasound Imaging

September 9, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), ultrasound color Doppler twinkling may ...

Time September 08, 2022
arrow
Subscribe Now